Licensed seasonal influenza vaccine

BIOLOGICAL3 trials

Sponsors

Altimmune, Inc., Novavax, GlaxoSmithKline

Conditions

COVID-19InfluenzaInfluenza, Human+COVID-19SARS-CoV-2 Infection

Phase 1

A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults

RecruitingNCT07464314

GlaxoSmithKlineInfluenza, Human+COVID-19

Start: 2026-03-09End: 2027-06-03Target: 225Updated: 2026-06-30

Phase 3

A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom

CompletedNCT04583995

NovavaxCOVID-19, SARS-CoV-2 Infection

Start: 2020-09-28End: 2022-03-29Updated: 2025-05-08

Phase 4

Immune Response Following Seasonal Influenza Vaccination

CompletedNCT03163342

Altimmune, Inc.Influenza

Start: 2017-05-08End: 2018-06-15Updated: 2019-04-26

Related Papers

Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial.

2021-11-17119 citations

Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial

PLoS Medicine2021-10-01112 citations